87% of HCPs believe payments from pharmaceutical companies to individually named healthcare professionals should be transparent, with around two thirds (64%) saying that this information should be publicly declared.
Two thirds (66%*) of HCPs with a current relationship with one or more pharmaceutical companies for which they receive payment or benefit in kind say that they have already given or are likely to give permission to the pharmaceutical companies they work with to disclose their payment information on the ABPI database when it launches on 30 June.